TPO and lymphoma: Currently, there’s no study that assessed TPO-RAs for treatment of CIT in patients with lymphoma, and it is unknown whether the two TPO-RAs, rhTPO and eltrombopag, are comparable with regard to the clinical effectiveness and tolerability in CIT treatment.